CASI Pharmaceuticals advances in kidney transplant treatment and explores strategic sale in China
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a notable player in the biopharmaceutical sector, has made a significant announcement that could have wide-reaching implications for kidney transplant ... Read More
Zydus Lifesciences gets FDA final approval for Rapamune generic – Sirolimus Tablets
Zydus Lifesciences has secured final approval from the US Food and Drug Administration (FDA) for Sirolimus Tablets, 1 mg and 2 mg, which is the ... Read More
Swiss biotech company Memo Therapeutics raises $15.5m in Series B round
Memo Therapeutics has raised CHF14 million ($15.56 million) in a Series B financing round towards the clinical development of potent antibodies for the immunotherapy of ... Read More
Talaris initiates FREEDOM-1 clinical trial for FCR001 in LDKT recipients
Talaris Therapeutics has initiated the phase 3 FREEDOM-1 clinical trial to evaluate its investigational, allogeneic cell therapy FCR001 in living donor kidney transplant (LDKT) recipients. ... Read More